The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma

• Published in: Journal of clinical oncology Vol. 40; no. 4_suppl; p. 453
• Main Authors: Zhang, Xiaoyun, Zhu, Xinrui, Liu, Chang, Lu, Wusheng, Li, Qiu, Chen, Weixia, Li, Zhiping, Lu, Qiang, Peng, Wei, Li, Chuan, Yan, Lvnan, Yang, Jiayin, Wen, Tianfu
• Format: Journal Article
• Language: English; Japanese
• Published: American Society of Clinical Oncology 01.02.2022

453Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC guidelines. There are few scientific trials...